ARIKAYCE liposomal 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/10882
Periodic Safety Update EU Single assessment - 
26/04/2023 
29/06/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202209 
amikacin (centrally authorised product only) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10882/202209. 
II/0008/G 
This was an application for a group of variations. 
20/10/2022 
n/a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IB/0007/G 
This was an application for a group of variations. 
31/05/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
Page 2/4 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.c.z - Container closure system of the AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
PSUSA/10882
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
amikacin (centrally authorised product only) 
IB/0005 
C.z - Safety, Efficacy, Pharmacovigilance changes - 
20/10/2021 
14/10/2022 
SmPC, 
Other variation 
Labelling and 
PL 
IA/0004 
A.7 - Administrative change - Deletion of 
24/08/2021 
n/a 
manufacturing sites 
IB/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/07/2021 
n/a 
Veterinary Medicinal Products - Other variation 
IA/0001/G 
This was an application for a group of variations. 
01/06/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
Page 4/4 
 
 
 
 
 
 
 
